微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 61.97% | -11.74% | -1.08% | 50/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 62.64% | -7.45% | -8.5% | 43/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 68.46% | -1.23% | -1.59% | 35/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 69.57% | 3.35% | -0.91% | 34/157 | 14.83% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 70.2% | 4.37% | 3.72% | 30/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 67.68% | 11.01% | -2.36% | 38/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 69.32% | 14.22% | 2.97% | 32/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 67.32% | 16.9% | 0.08% | 35/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 67.26% | 20.25% | 10.32% | 33/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 60.97% | 5.9% | 0.46% | 50/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 60.69% | 12.87% | 5.39% | 52/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 57.59% | 9.31% | 2.95% | 62/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 55.93% | 3.15% | -2.85% | 64/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 57.57% | 3.26% | 7.08% | 66/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 53.77% | -4.72% | 2.06% | 72/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.68% | -6.37% | -2.85% | 75/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 54.23% | -8.51% | -2.75% | 72/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 55.76% | -4.14% | -1.19% | 72/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 56.43% | 3.38% | 0.29% | 61/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 56.26% | -2.56% | -5.07% | 67/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 59.27% | 7.64% | 1.9% | 53/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 58.16% | 8.99% | 0.74% | 62/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 57.74% | -3.76% | 8.19% | 54/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 53.37% | -11.18% | -2.23% | 69/157 | -1242.15% | 微芯生物 | 95.14% | 行业排名> |
| 2019-09-30 | 54.58% | -15.69% | -9.02% | 54/157 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 60% | -8.43% | 8.96% | 48/157 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2019-03-31 | 55.06% | -17.47% | -8.36% | 53/157 | 51.07% | 微芯生物 | 96.09% | 行业排名> |
| 2018-12-31 | 60.09% | -2.5% | -7.19% | 52/157 | -211.97% | 微芯生物 | 96.11% | 行业排名> |
| 2018-09-30 | 64.74% | 2% | -1.19% | 28/157 | 54.14% | 微芯生物 | 95.5% | 行业排名> |
| 2018-06-30 | 65.52% | 17.71% | -1.8% | 27/157 | 53.53% | 微芯生物 | 96.27% | 行业排名> |
| 2018-03-31 | 66.72% | 2% | 8.26% | 28/157 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2017-12-31 | 61.63% | 26.37% | 10.72% | 40/157 | 52.55% | 贝达药业 | 95.51% | 行业排名> |
| 2017-06-30 | 55.66% | 504.65% | 14.14% | 36/157 | 47.91% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 48.77% | 2% | 429.76% | 51/157 | 48.46% | 贝达药业 | 95.74% | 行业排名> |
| 2016-06-30 | 9.21% | 2% | 2% | 87/157 | 46.26% | 退市金泰 | 96.19% | 行业排名> |